Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davood Semirani-Nezhad

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Biochemical Genetics|July 9, 2025
Circulating Levels of miR-155 and CTBP1-AS2 as a Promising Biomarker for Early Detection of Diabetic NephropathyArezoo Rahimi, Shekoofeh Nikooei, Khatere Roozbehi, et al.
The American Journal of Cardiology|December 31, 2025
Postoperative Atrial Fibrillation in Patients Undergoing Non-Cardiac SurgeryKhatere Roozbehi, Davood Semirani-Nezhad, Hamidreza Soleimani, et al.
American Journal of Nephrology|August 6, 2025
Intensive vs. Less Intensive Blood Pressure Control in Chronic Kidney Disease: A Systematic Review and Meta-analysis of Clinical TrialsParisa Fallahtafti, Davood Semirani-Nezhad, Saba Maleki, et al.
International Journal of Cardiology. Cardiovascular Risk and Prevention|February 24, 2026
Dose-dependent effects of SGLT2 inhibitors on circadian blood pressure in hypertensive patients with diabetes: A systematic review and Bayesian network meta-analysisDavood Semirani-Nezhad, Khatere Roozbehi, Arman Soltani Moghadam, et al.
Cardiovascular Therapeutics|June 18, 2026
Baseline Ejection Fraction as a Modifier of Beta-Blocker Therapeutic Effects in Post-Acute Coronary Syndrome Patients With Non-Reduced Ejection Fraction: A Systematic Review and Meta-AnalysisSeyed Alireza Mirhosseini, Seyed Amir Sadrzadeh, Davood Semirani-Nezhad, et al.
BMC Cardiovascular Disorders|July 19, 2025
Early initiation of SGLT2 inhibitors in acute myocardial infarction and cardiovascular outcomes, an updated systematic review and meta-analysisDavood Semirani-Nezhad, Hamidreza Soleimani, Morvarid Taebi, et al.
Diabetology & Metabolic Syndrome|February 25, 2025
Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trialsAsma Mousavi, Shayan Shojaei, Hamidreza Soleimani, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Biochemical Genetics|July 9, 2025
Circulating Levels of miR-155 and CTBP1-AS2 as a Promising Biomarker for Early Detection of Diabetic NephropathyArezoo Rahimi, Shekoofeh Nikooei, Khatere Roozbehi, et al.
The American Journal of Cardiology|December 31, 2025
Postoperative Atrial Fibrillation in Patients Undergoing Non-Cardiac SurgeryKhatere Roozbehi, Davood Semirani-Nezhad, Hamidreza Soleimani, et al.
American Journal of Nephrology|August 6, 2025
Intensive vs. Less Intensive Blood Pressure Control in Chronic Kidney Disease: A Systematic Review and Meta-analysis of Clinical TrialsParisa Fallahtafti, Davood Semirani-Nezhad, Saba Maleki, et al.
International Journal of Cardiology. Cardiovascular Risk and Prevention|February 24, 2026
Dose-dependent effects of SGLT2 inhibitors on circadian blood pressure in hypertensive patients with diabetes: A systematic review and Bayesian network meta-analysisDavood Semirani-Nezhad, Khatere Roozbehi, Arman Soltani Moghadam, et al.
Cardiovascular Therapeutics|June 18, 2026
Baseline Ejection Fraction as a Modifier of Beta-Blocker Therapeutic Effects in Post-Acute Coronary Syndrome Patients With Non-Reduced Ejection Fraction: A Systematic Review and Meta-AnalysisSeyed Alireza Mirhosseini, Seyed Amir Sadrzadeh, Davood Semirani-Nezhad, et al.
BMC Cardiovascular Disorders|July 19, 2025
Early initiation of SGLT2 inhibitors in acute myocardial infarction and cardiovascular outcomes, an updated systematic review and meta-analysisDavood Semirani-Nezhad, Hamidreza Soleimani, Morvarid Taebi, et al.
Diabetology & Metabolic Syndrome|February 25, 2025
Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trialsAsma Mousavi, Shayan Shojaei, Hamidreza Soleimani, et al.
Pageof 1